Early Onset Neutropenia due to Rituximab Therapy in Mantle Cell Lymphoma: A Case Report

Cases of late onset neutropenia (LON) after rituximab therapy have been documented, but few cases have been documented of early onset neutropenia (EON). We present a case report of a patient with mantle cell lymphoma who presented with EON, only 6 days after initiation of rituximab therapy, notable for the shortest duration to EON ever reported in literature. Throughout this paper, we explore the potential pathogenesis and incidence of EON with the help of our unique case.

[1]  J. Gribben,et al.  Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Woodley,et al.  Early‐onset neutropenia after rituximab therapy for bullous pemphigoid , 2018, Clinical and experimental dermatology.

[3]  B. Cheson,et al.  A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. , 2018, Blood advances.

[4]  R. Maciuca,et al.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. , 2012, Arthritis and rheumatism.

[5]  M. Lahav,et al.  Rituximab associated neutropenia: Description of three cases and an insight into the underlying pathogenesis , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[6]  J. Borrás-Blasco,et al.  Early onset neutropenia after rituximab in lupus nephritis. , 2007, Clinical and experimental rheumatology.

[7]  X. Mariette,et al.  Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. , 2007, Haematologica.

[8]  Y. Kanda,et al.  A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Dougados,et al.  Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases , 2004, Annals of the rheumatic diseases.

[10]  R. Mahfouz,et al.  Rituximab-induced acute thrombocytopenia: a report of two cases. , 2005, Haematologica.

[11]  P. Solal-Céligny,et al.  Neutropenia in patients treated with rituximab. , 2003, The New England journal of medicine.